Cyber Monday saleUp to 70% OFF
222

NOVMETA PHARMA

No trades
See on Supercharts
Overview
Financials Discussions Technicals Seasonals

229500 chart


Full chart

Key stats


Market capitalization
‪68.76 B‬ KRW
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
—
Net income (FY)
‪−12.56 B‬ KRW
Revenue (FY)
‪13.85 M‬ KRW
Shares float
‪7.42 M‬
Beta (1Y)
0.51

Employees


Employees (FY)
19
Change (1Y)
0
Revenue / Employee (1Y)
559.86 KRW
Net income / Employee (1Y)
‪−507.49 K‬ KRW

About NOVMETA PHARMA


Sector
Health Technology
Headquarters
Seoul
Founded
2010
Website
novmeta.com
ISIN
KR7229500004
FIGI
BBG00B9KQV77
NovMetaPharma Co., Ltd. engages in the manufacture and sale of biological drugs for insulin resistance and related metabolic diseases. Its business areas include new medicine development and healthy foods. Its products include medicines for diabetes, obesity, Alzheimer's disease, immunity cure, osteoporosis, and non-alcoholic fatty liver. The company was founded on November 4, 2010 and is headquartered in Seoul, South Korea.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 229500 is 6,080 KRW — it has decreased by −0.48% in the past 24 hours. Watch NOVMETA PHARMA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange NOVMETA PHARMA stocks are traded under the ticker 229500.
229500 stock has risen by 21.22% compared to the previous week, the month change is a 22.18% rise, over the last year NOVMETA PHARMA has showed a −70.20% decrease.
229500 reached its all-time high on Apr 18, 2018 with the price of 96,100 KRW, and its all-time low was 4,510 KRW and was reached on Sep 6, 2024. View more price dynamics on 229500 chart.
See other stocks reaching their highest and lowest prices.
229500 stock is 6.37% volatile and has beta coefficient of 0.51. Track NOVMETA PHARMA stock price on the chart and check out the list of the most volatile stocks — is NOVMETA PHARMA there?
Today NOVMETA PHARMA has the market capitalization of ‪68.76 B‬, it has increased by 1.41% over the last week.
Yes, you can track NOVMETA PHARMA financials in yearly and quarterly reports right on TradingView.
No, 229500 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 5, 2024, the company has 19.00 employees. See our rating of the largest employees — is NOVMETA PHARMA on this list?
Like other stocks, 229500 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVMETA PHARMA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVMETA PHARMA technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVMETA PHARMA stock shows the sell signal. See more of NOVMETA PHARMA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.